reported by all of the 123 reporting laboratories was 0.894 mg/L (0.128 mg/L, 14.3%). For the chronic kidney disease pool (ERM-DA471/IFCC-traceable target of 2.37 mg/L), the all-method mean (SD, %CV) was 2.258 mg/L (0.288 mg/L, 12.8%). There were substantial methodspecific biases (mean milligram per liter reported for the normal pool was 0.780 for Siemens, 0.870 for Gentian, 0.967 for Roche, 1.061 for Diazyme, and 0.970 for other/ not specified reagents; and mean milligram per liter reported for the chronic kidney disease pool was 2.052 for Siemens, 2.312 for Gentian, 2.247 for Roche, 2.909 for Diazyme, and 2.413 for other/not specified reagents).
Conclusions.-Manufacturers need to improve the accuracy of cystatin C measurement procedures if cystatin C is to achieve its full potential as a biomarker for estimating glomerular filtration rate.
(Arch Pathol Lab Med. 2015;139:888-893; doi: 10.5858/ arpa.2014-0427-CP) C ystatin C is a 13.3-kDa protein that is produced by all nucleated cells and is present in blood in rising concentrations as a person's glomerular filtration rate (GFR) declines. Cystatin C has been proposed as an adjunct to blood creatinine measurements to improve the accuracy of estimated glomerular filtration rate (eGFR) in appropriate clinical conditions. [1] [2] [3] [4] Besides its usefulness in estimating GFR, serum or plasma cystatin C has been reported to be a better predictor of all-cause mortality than serum creatinine. 5 These observations have led to several GFRestimating equations for both adults and children, using a combination of cystatin C and creatinine concentrations as well as cystatin C alone. 2, 3, [6] [7] [8] [9] [10] [11] One of the major problems with any new biomarker is that laboratories using different measurement procedures, and even those allegedly using the same measurement procedure, do not always report the same concentration for a given clinical sample. Consequently, the calculated eGFR values using these measured concentrations show similar variability.
To reduce the variability in cystatin assays among clinical laboratories, the International Federation for Clinical Chemistry and Laboratory Medicine (IFCC) Working Group on Standardization of Cystatin C succeeded in preparing international reference material. 11, 12 This reference material is distributed by the European Commission Joint Research Centre, Institute for Reference Materials and Measurements in Geel, Belgium, as certified reference material ERM-DA471/IFCC and first became available to manufacturers of cystatin C reagents and clinical laboratories in late 2010.
One of the largest proficiency testing programs for cystatin C is the College of American Pathologists (CAP) CYS Survey, which began in 2011. The proficiency testing materials distributed in this survey before 2014 were all prepared by adding cystatin C, which was partially purified from human blood, to processed human plasma to produce varying concentrations of cystatin C. Generally, one normal and one slightly elevated cystatin C concentration were produced to simulate both a sample from a patient with normal renal function and one with chronic kidney disease (CKD). Data from the 2011 through 2013 CAP CYS surveys that used these artificially processed samples showed substantial variability in reported results among, and even within, a single in vitro diagnostics manufacturer's cystatin C measurement procedure. To a large extent, the quite striking method-specific biases were dismissed as being caused by noncommutability due to the artificial nature of the CYS Survey proficiency testing materials being distributed. To produce a proficiency testing material that would not suffer from noncommutability issues, we prepared 2 different pools of off-the-clot, fresh frozen human serum for distribution to laboratories participating in the 2014 CAP CYS-A Survey in April 2014. Our goal was to evaluate the variability among and within measurement procedures currently used by clinical laboratories, using materials that more accurately represent clinical samples.
METHODS
The 2014 CAP CYS-A Survey challenge was distributed in late April to 141 participating laboratories of which 42% were non-US laboratories in 20 different countries. The survey included 4 proficiency testing samples rather than the usual 2. The first 2 samples (CYS-01 and CYS-02) were the typical ''processed human plasma'' to which cystatin C was added and were similar to those distributed to CYS Survey participating laboratories in 2011 through 2013. The second 2 ''wild card'' samples (CYS-WC1 and CYS-WC2) were the 2 pools prepared from off-the-clot, fresh frozen human serum with no other manipulations and nothing else added to them. The CYS-WC1 sample was serum pooled from 8 apparently healthy volunteers at the University of Minnesota, Minneapolis. As expected, it had a cystatin C concentration toward the middle of the normal adult reference range. The CYS-WC2 sample was serum pooled from 9 patients with CKD who were being seen regularly in the Kidney Disease and Blood Pressure Center at Tufts Medical Center, Boston, Massachusetts. All donors contributing to the pools were first confirmed to be negative for hepatitis B surface antigen, hepatitis B core antibody, hepatitis C antibody, and antibody to human immunodeficiency virus 1 and 2, and all gave informed consent. Both the University of Minnesota and Tufts Medical Center institutional review boards reviewed and approved blood collection for this purpose.
To establish ERM-DA471/IFCC-traceable target values for the 2 wild-card samples, we first carefully prepared 2-and 6-fold dilutions of the ERM-DA471/IFCC certified reference material (European Commission, Joint Research Centre, Institute for Reference Materials and Measurements, Geel, Belgium) and we confirmed our dilutions' accuracy gravimetrically. We next analyzed these materials along with the CYS-WC1 and CYS-WC2 samples, in triplicate on 2 different days by using 2 clinical measurement procedures: Siemens ProSpec instrument using Siemens reagents and Siemens calibrators (Siemens Healthcare Diagnostics, Inc, Tarrytown, New York) and the Roche COBAS 6000 (Roche Diagnostics Corporation, Indianapolis, Indiana) instrument using Gentian reagents and Gentian calibrators (Gentian, Moss, Norway) in the University of Minnesota Advanced Research and Diagnostic Laboratory (Minneapolis). Using the mean values for a 2-fold diluted and a 5-fold diluted ERM-DA471/IFCC reference material (certified value of 5.48 6 0.15 mg/L expanded uncertainty with coverage factor k ¼ 2 corresponding to a level of confidence of approximately 95%), we constructed a 2-point calibration line for the instrument response versus the diluted ERM-DA471/IFCC calculated values as the reference. From that calibration relationship for each measurement procedure, we then computed the concentration in each of the 2 wild-card samples, corrected to be traceable to the ERM-DA471/IFCC-assigned certified value. We were encouraged that the ERM-DA471/IFCC-traceable values for the 2 off-the-clot serum pools from the ProSpec and from the COBAS data gave results within 1% of each other, so they were averaged, yielding final target values of 0.96 and 2.37 mg/L, for CYS-WC1 and CYS-WC2, respectively. Since the undiluted ERM-DA471/IFCC reference material's certified value is stated to have an approximately 62.7% uncertainty, we estimated the uncertainty in these target values to be approximately 3% to 4% (expanded uncertainty with coverage factor k ¼ 2). Values were not assigned to CYS-01 and CYS-02 because of concerns that noncommutability would lead to spurious assigned values.
Participating laboratories were asked to measure the cystatin C concentration of the 4 survey samples only once as they would for any clinical sample or other CAP survey sample and to report their concentration on a usual CAP survey result form. Laboratories were also asked to respond to several supplementary questions about the instrument platform, the reagent, the calibrator, and the specific lot number of the calibrator that they used for their cystatin C measurements.
Results for each of the survey samples were grouped by reagent/ calibrator ''method'' group when 8 or more laboratories indicated in the supplementary questions that they used a single manufacturer's reagent and calibrator for their cystatin C measurements. The reagent/calibrator method groups with 8 or more laboratory users were Siemens, Roche, Gentian, and Diazyme (Diazyme Laboratories, Poway, California). When there were fewer than 8 laboratories using a single manufacturer's reagent/calibrator system, when a laboratory indicated they used a different manufacturer's calibrator from the reagent system used, or when a laboratory simply failed to answer the supplementary question about reagent and calibrator used, they were classified into an ''other/not specified'' group for purposes of method-specific grouping during data analysis. To detect grossly aberrant ''outlier'' values, we first computed the mean and standard deviation (SD) for each survey sample for all reported results. Then any reported values greater than 3 SD from the all-method mean, which were most likely due to some instrument malfunction or clerical error, were excluded from any further analyses.
RESULTS
Of the 141 laboratories enrolled in the CYS Survey, there were 132 laboratories which returned at least some results for the 2014 CYS-A mailed samples and 124 returned data for the fresh frozen CYS-WC1 and CYS-WC2 samples. Of these 124 laboratories, 52 (42%) were from outside the United States, but non-US locations varied slightly with specific method. Several laboratories that reported cystatin C concentrations for the other 3 proficiency testing samples failed to report any results for the CYS-02 sample, likely because the results were below the lower limit of their acceptable analytic measurement range. For reasons unknown, occasional results for other samples were simply not reported. In addition, several laboratories reporting results for the usual proficiency testing samples (CYS-01 and CYS-02) opted not to report results for the wild-card samples. A single extreme outlier for each of the 4 different survey samples was identified and removed before any further data analysis by using a greater than 3 SD exclusion rule: a CYS-01 result of 2.49 mg/L, a CYS-02 result of 2.07 mg/L, a CYS-WC1 result of 0.14 mg/L, and a CYS-WC2 result of 7.39 mg/L.
The Gentian and Diazyme reagents and calibrators were used in conjunction with 4 and 5 different instrument platforms, respectively. In contrast, all but 1 laboratory in the Roche reagent group used 1 of 3 Roche instrument platforms. All laboratories using Siemens reagent and calibrators used 1 of 3 Siemens instrument platforms (BNII, ProSpec, or Vista).
The mean, SD, and coefficient of variation (CV) of the cystatin C results for each of the 4 samples that were reported by the participating laboratories are shown in the Table. The mean values cannot be reliably compared for the 2 processed human plasma samples because these are not expected to be commutable with patient samples. The CVs within each clearly defined reagent/calibrator method group varied from 2.0% to 10.2% for the CYS-01 processed sample with a concentration in the mildly elevated range, and from 9.3% to 19.5% for the CYS-02 processed sample, which had a very low cystatin C concentration.
Results for the 2 off-the-clot wild-card serum samples are more informative because these are expected to be commutable with patient samples and thus appropriately reflect the current status of harmonization among different routine methods. The CVs within the reagent groups were similar to those observed for the conventional samples. The range of method-specific mean values for sample CYS-WC1, with target value 0.96 mg/L, varied from 0.78 to 1.06 mg/L (29%); and for sample CYS-WC2, with target value 2.37 mg/L, varied from 2.05 to 2.91 mg/L (36%). Frequency distributions of all method results for the 2 wild-card samples are shown in Figures 1 and 2 , which show a nearly 2-fold variation among all laboratories reporting cystatin C concentrations. Figures 3 through 6 show the method-specific individual results graphically for the 2 wild-card samples as well as the all-method 2.5th, 25th, 50th (median), 75th, and 97.5th percentiles and for the CYS-WC1 and CYS-WC2 samples, Abbreviations: CV, coefficient of variation (SD divided by the mean 3 100); N, number of laboratories using a single manufacturer's reagent and calibrator system; SD, standard deviation. a Results from laboratories using a single manufacturer's reagent and calibrator system were grouped as described in the text. The following manufacturers had 8 or more users of their reagents and calibrators: Siemens Healthcare Diagnostics, Inc, Tarrytown, New York; Gentian, Moss, Norway; Roche Diagnostics Corporation, Indianapolis, Indiana; and Diazyme Laboratories, Poway, California. Since many of the participants in the College of American Pathologists CYS Survey were international laboratories, some laboratories likely procured their reagents and calibrators from non-US affiliates of these companies. When there were fewer than 8 laboratories using a single manufacturer's reagent/calibrator system, when a laboratory indicated they used a different manufacturer's calibrator from the reagent system used, or when a laboratory simply failed to answer the supplementary question about reagent and calibrator used, they were classified into an ''other/not specified'' group. 
CONCLUSION
Noncommutable reference materials have created problems in interpretation of proficiency testing results for many measurands (analytes). Noncommutability arises when the matrix of a reference material being used as either calibrator or as a proficiency testing (external quality assessment) material is sufficiently different than that of typical patient samples, such that the resulting measurement is not an accurate reflection of the performance expected for patient samples. [13] [14] [15] We believe that use of human samples, which are more likely representative of performance on real clinical samples, is most important for determining variability across different measurement procedures. Use of commutable samples for assessing the performance of cystatin C measurements showed substantial variability in results by participating laboratories. This variability seriously compromises the effective use of cystatin C in clinical practice and research. Manufacturers need to improve the performance Figure 3 . Individual participating laboratories reported cystatin C results sorted by individual method-specific group for 2014 CYS-A Survey sample CYS-01. Horizontal bar within each method-specific set of data points represents the mean value reported for that method-specific group. The ''box and whisker'' representation on the right side of the figure shows the all-method results for survey sample CYS-01: the 25th, 50th (median), and 75th percentiles are represented by the bottom border, the center line, and the top border of the box, respectively, while the whiskers show the 2.5th and 97.5th percentile values. Figure 4 . Individual participating laboratories reported cystatin C results sorted by individual method-specific group for 2014 CYS-A Survey sample CYS-02. Horizontal bar within each method-specific set of data points represents the mean value reported for that method-specific group. The ''box and whisker'' representation on the right side of the figure shows the all-method results for survey sample CYS-02: the 25th, 50th (median), and 75th percentiles are represented by the bottom border, the center line, and the top border of the box, respectively, while the whiskers show the 2.5th and 97.5th percentile values.
of routine methods and laboratories need to select only the better performing methods.
The Roche and Gentian measurement procedures appeared to be the most accurate with either the lowest bias or variability among different laboratories. In the case of Gentian, better accuracy was observed even though laboratories used those reagents and calibrators with instrument platforms from 4 different manufacturers.
The Siemens results for both the CYS-WC1 and CYS-WC2 samples had a substantial negative bias. A negative bias for Siemens' nephelometric cystatin C results relative to ERM-DA471/IFCC-traceable target values has been previously reported and appears to have developed gradually over many years from a calibration drift. 16 In fact, a numeric correction of Siemens' results before their use with any Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) cystatin C-based eGFR equations has been suggested for laboratories that measure cystatin C by using Siemens reagents, calibrators, and instrument systems. 17 Siemens acknowledges that their nephelometric systems distributed in the United States give results that are not traceable to ERM-DA471/IFCC because the necessary recalibration has been delayed by concerns related to US Food and Drug Administration approvals necessary to perform a recalibration of their measurement procedure. However, Siemens reagents, calibrator, and instrument systems that are distributed outside the United States have reportedly been recalibrated to yield ERM-DA471/IFCC-traceable results. Based on the data for non-US laboratories, the Siemens results still had substantial negative biases versus the ERM-DA471/IFCC-traceable target values. The results for the non-US laboratories were statistically significantly different Figure 5 . Individual participating laboratories reported cystatin C results sorted by individual method-specific group for 2014 CYS-A Survey sample CYS-WC1. Horizontal bar within each method-specific set of data points represents the mean value reported for that method-specific group. The ''box and whisker'' representation on the right side of the figure shows the all-method results for survey sample CYS-WC1: the 25th, 50th (median), and 75th percentiles are represented by the bottom border, the center line, and the top border of the box, respectively, while the whiskers show the 2.5th and 97.5th percentile values. The horizontal dashed line shows the ERM-DA471/IFCC-traceable target value. Pathologists CYS Survey were international laboratories, some laboratories likely procured their reagents and calibrators from non-US affiliates of these companies. When there were fewer than 8 laboratories using a single manufacturer's reagent/calibrator system, when a laboratory indicated they used a different manufacturer's calibrator from the reagent system used, or when a laboratory simply failed to answer the supplementary question about reagent and calibrator used, they were classified into an ''other'' group. from those for the US laboratories, which had a larger negative bias. The geographic variation in calibration partially explains why the Siemens method-specific group had a larger SD and CV.
Laboratories using the Diazyme measurement procedure had cystatin C results with a substantial positive bias relative to the ERM-DA471/IFCC-traceable target values, despite the fact that the manufacturer claims calibration traceability to the ERM-DA471/IFCC reference material. The Diazyme reagent grouping also had the highest within-group SD and CV for both fresh frozen wild-card samples. This variability in results may be partly due to the fact that laboratories using Diazmye reagents and calibrators reported using the widest assortment of instrument platforms. However, a common calibrator is supposed to make results among instrument platforms comparable, which in this case appears to have been less effective than for other reagent/ calibrator systems. It is also noteworthy that the Diazyme mean value was the furthest from the ERM-DA471/IFCCtraceable target values for the CYS-WC2 sample and also had a substantial positive bias for the CYS-WC1 fresh frozen serum. In the past, a consistently high bias of the Diazyme results had been attributed to noncommutability of CAP's conventional CYS Survey samples, but it now appears not to be simply a noncommutability artifact but also reflects inaccurate calibration traceability to the ERM-DA471/IFCC reference material.
The other/not specified reagent/calibrator group's results on CYS-WC1 and CYS-WC2 had mean values that agreed well with the ERM-DA471/IFCC-traceable target values, but this reagent/calibrator method group had the largest variability among laboratories. It is difficult to explain the source of variability because it is unclear what measurement procedures, instruments, reagents, or calibrators these laboratories were using.
The variability in cystatin C concentrations observed for the 2 fresh frozen serum pools can be related to the variability in the reported eGFR values. For example, the central 95% (2.5th to 97.5th percentile) for all methods for the CYS-WC1 sample went from approximately 0.70 to 1.22 mg/L. In a 50-year-old man, these cystatin C concentrations would yield an eGFR, using the 2012 CKD-EPI equation 2 In past CAP CYS surveys, the CAP method coding has at times produced somewhat heterogeneous admixtures of reagent, calibrator, and instrument systems within a single ''method-specific'' group. For example, a laboratory using Gentian reagents and calibrators on a Roche COBAS instrument might choose Gentian (CAP's CYS Survey's code 1921) as its ''method code,'' while other laboratories using the same instrument/reagent/calibrator system might chose Roche COBAS Integra (CAP's CYS Survey's code 1807) as their method code. Consequently, laboratories using the exact same instrument, reagent, and calibrator system often ended up in different method-specific groups, particularly for open-instrument platforms where a variety of reagents and calibrator systems can be used, making assessment of performance misleading. One of the strengths of the current study is that we present a more complete analysis based on reagent/calibrator groupings taken from the responses to supplemental questions that clarified the specific instrument, reagent, and calibrator that were used by various laboratories. Another major strength of this study is the use of off-the-clot fresh frozen serum for the 2 wildcard samples. These samples were expected to be commutable with clinical patient samples and thus to give a reliable assessment of method performance.
In summary, despite the availability of an international reference material for more than 3 years, the variability in cystatin C measured values with several widely used clinical measurement procedures appears to be too large for the values to be very useful for diagnosing and managing patients with kidney disease. Several manufacturers of in vitro diagnostics reagents and instrument systems designed for measurement of cystatin C concentration need to improve dramatically the calibration traceability to the ERM-DA471/IFCC reference material, as well as reduce the variability in reported results from laboratories using their methods, before cystatin C will be a useful clinical biomarker for diagnosis of CKD.
